Doxorubicin is an anthracycline antibiotic commonly used as a chemotherapeutic agent in the treatment of various malignancies. It is a red, crystalline compound with the molecular formula C₂₇H₂₉NO₁₁ and a molecular weight of 543.52 g·mol⁻¹. Doxorubicin is commercially available under several brand names, including Adriamycin® and Doxorubicin Hydrochloride.
Chemical Structure and Properties
- Class: Anthracycline antibiotic
- IUPAC name: (8S,13S)-13‑[(2‑hydroxy‑1‑hydroxymethyl‑2‑oxopropyl)amino]‑8‑hydroxy‑6,11‑dimethoxy‑1‑phenyl‑3‑methoxy‑2,10‑dihydro‑8,15‑dioxo‑9‑(2‑hydroxyethyl)‑15‑(2‑hydroxy‑2‑hydroxyethoxy)‑1,2,3‑trihydro‑10,15‑dihydroxy‑7,8‑dihydro‑6‑oxo‑12‑yl‑tetracycline.
- Physical state: Red‑brown powder, poorly soluble in water; formulated as a hydrochloride salt for injection.
Mechanism of Action
Doxorubicin intercalates between DNA base pairs, inhibiting the progression of the enzyme topoisomerase II during the transcription and replication processes. This interference leads to DNA strand breaks and the generation of free radicals, contributing to cytotoxicity. The drug’s ability to generate reactive oxygen species is also implicated in its antitumor activity and some of its dose‑limiting toxicities.
Pharmacokinetics
- Administration: Intravenous infusion (bolus or continuous).
- Distribution: Widely distributed throughout body tissues; extensive protein binding (~75 %).
- Metabolism: Primarily hepatic, undergoing reduction to doxorubicinol, an active metabolite with similar cytotoxic properties.
- Elimination: Biphasic plasma clearance with a terminal half‑life of approximately 20–48 hours; excreted mainly via bile.
Clinical Indications
Doxorubicin is indicated for a broad spectrum of solid tumors and hematologic malignancies, including:
- Breast cancer (both early‑stage and metastatic)
- Non‑Hodgkin lymphoma
- Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
- Hodgkin lymphoma
- Soft‑tissue sarcomas (e.g., leiomyosarcoma, liposarcoma)
- Ovarian cancer
- Cervical cancer
- Small‑cell lung carcinoma
It is frequently incorporated into combination chemotherapy regimens (e.g., CHOP, ABVD, AC) to enhance therapeutic efficacy.
Adverse Effects
The toxicity profile of doxorubicin includes:
- Myelosuppression: Neutropenia, anemia, thrombocytopenia.
- Cardiotoxicity: Cumulative dose‑related cardiomyopathy and congestive heart failure; risk increases markedly at cumulative doses > 450 mg/m².
- Mucositis: Inflammation of the oral and gastrointestinal mucosa.
- Alopecia: Hair loss is common and typically reversible.
- Nausea and vomiting: May be prophylactically managed with antiemetics.
- Secondary malignancies: Rarely, therapy‑related acute leukemias have been reported.
Cardiotoxicity is the primary dose‑limiting factor; monitoring includes baseline and periodic evaluation of left ventricular ejection fraction (LVEF) via echocardiography or radionuclide ventriculography.
Contraindications and Precautions
- Known hypersensitivity to doxorubicin or other anthracyclines.
- Pre‑existing severe cardiac dysfunction.
- Pregnancy and lactation: Doxorubicin is classified as Pregnancy Category D (teratogenic and embryotoxic) and is contraindicated.
Drug Interactions
- Cardioprotective agents: Dexrazoxane is approved for reducing anthracycline‑induced cardiotoxicity.
- Antagonistic agents: Concurrent use of certain antioxidants (e.g., high‑dose vitamin E) may theoretically reduce efficacy, though clinical significance remains uncertain.
- Pharmacokinetic modifiers: CYP3A4 inducers or inhibitors can alter doxorubicin metabolism; dose adjustments may be required.
History and Development
Doxorubicin was first isolated in 1969 from the soil bacterium Streptomyces peucetius by researchers at the Lederle Laboratories (now part of Pfizer). Its antitumor activity was rapidly recognized, leading to FDA approval in 1974 for the treatment of advanced breast cancer. Since its introduction, doxorubicin has become a cornerstone of oncology therapy and a prototype for the development of subsequent anthracycline derivatives (e.g., epirubicin, idarubicin).
Regulatory and Patent Status
The original patents for doxorubicin have expired, allowing the production of generic formulations worldwide. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved doxorubicin for the indications listed above, subject to national labeling requirements and post‑marketing surveillance.
Research and Emerging Applications
Current investigations involve liposomal encapsulation (e.g., pegylated liposomal doxorubicin) to improve therapeutic index by reducing cardiotoxicity and enhancing tumor delivery. Clinical trials continue to evaluate novel combinations with targeted therapies, immune checkpoint inhibitors, and radiosensitizers.
References
(Encyclopedic entries typically cite primary literature, pharmacopoeias, and regulatory documents; detailed references are omitted here for brevity.)